Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B21 adjuvant pembrolizumab in high-risk endometrial cancer
2022-501973-37-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) and endometrial carcinosarcoma comparing Pembrolizumab arm with Placebo arm (2 arms). Primary endpoints: Disease-Free Survival and Overall Survival. Planned start Jan 2020; status: authorised.
02
Drugs
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on 2022-501973-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501973-37-00.